Searched for
LUPIN SHARE PRICES
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Two Trades for Today: A leading pharma firm for a 5.75% rise, a mid-cap online insurance stock for a gain of almost 6%Our technical analysts identify select stocks on every trading day that may gain momentum even in volatile markets. Here are the technical ...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drugLupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement...
- Lupin shares in focus as USFDA inspection at Somerset facility concludes with no observationsEarlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 manufacturing facili...
- Lupin shares zoom up to 15% in last 2 weeks. Analysts predict further gainsLupin shares continue to rise, trading at a new 52-week high of Rs 2,376 after a 15% return over two weeks. The Nifty Pharma index's Decemb...
- Share price of Lupin as NiftyA total of 8,636 shares changed hands on the counter till 01:42PM (IST).
- Lupin shares surge 6%, hit 52-week high post robust Q1 resultLupin Share Price: Lupin's shares jumped 6% to a 52-week high after the company announced a 77.2% increase in net profit for the June quart...
- Lupin shares jump over 8% after September quarter resultsManufacturing and other expenses were 30% of sales at Rs 1,226.8 crore compared to Rs 1,191.6 crore in Q1 FY2023. Investment in R&D for the...
- Lupin skids as failed USFDA specifications lead to recalls of 2 drugsThe company’s scrip fell to a low of Rs 937.15 as against Rs 951.80 at previous close on the National Stock Exchange.
- Lupin gains 1% on tentative USFDA nod to generic BrexpiprazoleAt 09:30 hours (IST), Lupin’s shares traded at Rs 957.70 on the National Stock Exchange, up 1.11% from previous close.
- Rakesh Jhunjhunwala’s third biggest stock bet not in the pink of healthInvestors looking for safer bets and craving for returns in an uncertain market are taking shelter in these defensive bets.
- Irish drug regulator clears Lupin Pune unit after virtual inspectionLupin’s Pune facility is known for its R&D and manufacturing work related to biosimilars.
Load More
